Dr. Clifford A. Hudis on Why Resistance to HER-2 Therapies Needs to be Further Researched
Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, talks about the vague understanding medical professional currently have of HER-2 breast cancer and its resistance to certain therapies.
Clifford A. Hudis, MD, FACP, Vice President for Government Relations and Chief Advocacy Officer, Chief, Breast Medicine Service at Memorial Sloan Kettering Cancer Center, talks about the vague understanding medical professionals currently have of HER-2 breast cancer and its resistance to certain therapies.
Hudis explains that while some studies have suggested that patients would be better off switching therapies due to breast cancer not responding to the treatment, further studies have shown that the benefits of staying with those therapies may outweigh the negative effects. Hudis says that this is a challenge to the idea of drug resistance itself.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
